Efficacy, Immunogenicity and Safety of BBIBP-CorV Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.
Condition(s):COVID-19 DiseaseLast Updated:August 16, 2021Not yet recruiting
Include Studies Not Open or Pending
Condition(s):COVID-19 DiseaseLast Updated:August 16, 2021Not yet recruiting
Condition(s):SARS-CoV2 InfectionLast Updated:April 20, 2023Recruiting
Condition(s):Covid-19; Subjects Vaccinated Against Covid-19Last Updated:August 29, 2022Recruiting
Condition(s):AnosmiaLast Updated:May 27, 2022Not yet recruiting
Condition(s):Multiple Sclerosis; COVID-19 (Severe Coronavirus Disease 2019)Last Updated:April 19, 2022Recruiting
Condition(s):SARS-CoV-2; Influenza A; Influenza B; Asymptomatic COVID-19Last Updated:May 8, 2023Not yet recruiting
Condition(s):SARS-CoV-2 InfectionLast Updated:October 5, 2022Not yet recruiting
Condition(s):COVID-19Last Updated:September 8, 2022Recruiting
Condition(s):Sars-CoV2Last Updated:August 3, 2022Recruiting
Condition(s):SARS-CoV-2; COVID-19; Post-Acute COVID-19 SyndromeLast Updated:February 20, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.